This post is from a suggested group
How Drug Eluting Balloons Are Transforming Endovascular Care
Drug eluting balloons (DEBs) have emerged as one of the most impactful technologies in vascular treatment. They combine mechanical dilation with localized drug delivery, reducing the risk of restenosis while preserving vessel integrity. Unlike stents, which remain implanted, DEBs leave no permanent metal structure behind. This “leave-nothing-behind” philosophy allows for natural vessel movement, reduces inflammatory reaction, and provides long-term flexibility in future interventions.
DEBs are coated with drugs such as paclitaxel or sirolimus—agents known for preventing excessive tissue growth inside blood vessels. When the balloon inflates, the drug is transferred directly onto the vessel wall in a controlled, homogeneous manner. This targeted approach reduces the likelihood of scar tissue formation, one of the main causes of artery re-narrowing after conventional angioplasty.
A major benefit of DEBs is their versatility. They are used in peripheral artery disease, coronary artery disease, hemodialysis access maintenance, and even in some emerging non-vascular applications. Because…